Nanobiotix FY2024 EPS Estimate Raised by Leerink Partnrs

Nanobiotix S.A. (NASDAQ:NBTX - Free Report) - Stock analysts at Leerink Partnrs upped their FY2024 earnings per share estimates for Nanobiotix in a research note issued on Tuesday, March 18th. Leerink Partnrs analyst J. Chang now expects that the company will post earnings of ($0.94) per share for the year, up from their prior estimate of ($1.22). The consensus estimate for Nanobiotix's current full-year earnings is ($1.18) per share. Leerink Partnrs also issued estimates for Nanobiotix's FY2025 earnings at ($0.51) EPS and FY2026 earnings at $0.84 EPS.

Separately, UBS Group raised Nanobiotix to a "hold" rating in a research report on Monday, February 17th.

Nanobiotix Price Performance

NBTX traded down $0.04 on Friday, hitting $3.62. 6,744 shares of the company's stock were exchanged, compared to its average volume of 22,054. The stock has a fifty day moving average of $3.52 and a two-hundred day moving average of $3.88. Nanobiotix has a twelve month low of $2.76 and a twelve month high of $7.51.

Institutional Trading of Nanobiotix

A number of hedge funds and other institutional investors have recently made changes to their positions in NBTX. OLD Mission Capital LLC acquired a new stake in Nanobiotix in the fourth quarter worth approximately $139,000. Jane Street Group LLC bought a new stake in shares of Nanobiotix in the 4th quarter worth $73,000. Millennium Management LLC acquired a new stake in shares of Nanobiotix in the fourth quarter valued at $39,000. Finally, Geode Capital Management LLC bought a new position in Nanobiotix during the fourth quarter valued at about $29,000. 38.81% of the stock is currently owned by institutional investors.

Remove Ads

About Nanobiotix

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.